{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T12:29:33Z","timestamp":1753273773923,"version":"3.40.5"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","msard-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.msard.2024.105733","type":"journal-article","created":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T16:27:42Z","timestamp":1718641662000},"page":"105733","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Analysis of Evusheld safety and efficacy in multiple sclerosis patients"],"prefix":"10.1016","volume":"88","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0005-0425","authenticated-orcid":false,"given":"Emilie N.","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcos","family":"Real","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer H.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashley","family":"Fair","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalie","family":"Whitmire","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allyssa","family":"Perez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolyn","family":"Wilder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shauna","family":"Rosengren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Revere P.","family":"Kinkel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer S.","family":"Graves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2024.105733_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2021.577746","article-title":"Humoral immune response in multiple sclerosis patients following PfizerBNT162b2 COVID19 vaccination: up to 6 months cross-sectional study","volume":"361","author":"Achiron","year":"2021","journal-title":"J. Neuroimmunol."},{"issue":"1","key":"10.1016\/j.msard.2024.105733_bib0013","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.amjmed.2022.08.019","article-title":"The prevention of COVID-19 in high-risk patients using tixagevimab-cilgavimab (Evusheld): real-world experience at a large academic center","volume":"136","author":"Al-Obaidi","year":"2023","journal-title":"Am. J. Med."},{"issue":"4","key":"10.1016\/j.msard.2024.105733_bib0014","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1001\/jama.2021.24931","article-title":"Tixagevimab and cilgavimab (Evusheld) for Pre-exposure prophylaxis of COVID-19","volume":"327","author":"Anon","year":"2022","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.msard.2024.105733_bib0003","doi-asserted-by":"crossref","first-page":"e24971","DOI":"10.1097\/MD.0000000000024971","article-title":"Comorbidities\u2019 potential impacts on severe and non-severe patients with COVID-19: a systematic review and meta-analysis","volume":"100","author":"Cheng","year":"2021","journal-title":"Medicine"},{"key":"10.1016\/j.msard.2024.105733_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103905","article-title":"Tixagevimab and cilgavimab (Evusheld) boosts antibody levels to SARS-CoV-2 in patients with multiple sclerosis on b-cell depleters","volume":"63","author":"Conte","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"10077","key":"10.1016\/j.msard.2024.105733_bib0020","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1016\/S0140-6736(17)30398-7","article-title":"Inequality and the health-care system in the USA","volume":"389","author":"Dickman","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.msard.2024.105733_bib0010","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.763412","article-title":"COVID-19 in B cell-depleted patients after rituximab: a diagnostic and therapeutic challenge","volume":"12","author":"Furlan","year":"2021","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.msard.2024.105733_bib0001","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jmii.2020.05.001","article-title":"A systematic review of asymptomatic infections with COVID-19","volume":"54","author":"Gao","year":"2021","journal-title":"J. Microbiol. Immunol. Infect."},{"key":"10.1016\/j.msard.2024.105733_bib0012","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1219560","article-title":"Immune response to SARS-CoV-2 mRNA vaccination in multiple sclerosis patients after rituximab treatment interruption","volume":"14","author":"Gr\u00f6ning","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.msard.2024.105733_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103785","article-title":"The humoral response to SARS-COV-2 vaccines in MS patients: a case series exploring the impact of DMT, lymphocyte count, immunoglobulins, and vaccine type","volume":"61","author":"Jakubecz","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"34","key":"10.1016\/j.msard.2024.105733_bib0021","doi-asserted-by":"crossref","first-page":"4180","DOI":"10.1016\/j.vaccine.2015.04.040","article-title":"Strategies for addressing vaccine hesitancy - A systematic review","volume":"33","author":"Jarrett","year":"2015","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.msard.2024.105733_bib0019","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2021.1950504","article-title":"COVID-19 vaccine hesitancy: misinformation and perceptions of vaccine safety","volume":"18","author":"Kricorian","year":"2022","journal-title":"Hum. Vaccin. Immunother"},{"issue":"23","key":"10.1016\/j.msard.2024.105733_bib0007","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1056\/NEJMoa2116620","article-title":"Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for prevention of COVID-19","volume":"386","author":"Levin","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.msard.2024.105733_bib0016","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1016\/j.cell.2021.02.042","article-title":"SARS-CoV-2 501Y.V2 variants lack higher infectivity but do have immune escape","volume":"184","author":"Li","year":"2021","journal-title":"Cell"},{"issue":"635","key":"10.1016\/j.msard.2024.105733_bib0015","doi-asserted-by":"crossref","first-page":"eabl8124","DOI":"10.1126\/scitranslmed.abl8124","article-title":"The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in nonhuman primates and has an extended half-life in humans","volume":"14","author":"Loo","year":"2022","journal-title":"Sci. Transl. Med."},{"issue":"1","key":"10.1016\/j.msard.2024.105733_bib0011","doi-asserted-by":"crossref","first-page":"e1037","DOI":"10.1093\/cid\/ciab954","article-title":"Robust T-cell responses in anti-CD20-treated patients following COVID-19 vaccination: a prospective cohort study","volume":"75","author":"Madelon","year":"2022","journal-title":"Clin. Infect. Dis."},{"issue":"6","key":"10.1016\/j.msard.2024.105733_bib0008","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1093\/cid\/ciac855","article-title":"Effectiveness of evusheld in immunocompromised patients: propensity score-matched analysis","volume":"76","author":"Najjar-Debbiny","year":"2023","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.msard.2024.105733_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102195","article-title":"B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran","volume":"43","author":"Safavi","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2024.105733_bib0018","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.830527","article-title":"Omicron: a heavily mutated SARS-CoV-2 variant exhibits stronger binding to ACE2 and potently escapes approved COVID-19 therapeutic antibodies","volume":"12","author":"Shah","year":"2022","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.msard.2024.105733_bib0002","doi-asserted-by":"crossref","first-page":"202","DOI":"10.3390\/v13020202","article-title":"COVID-19: a Review on the novel coronavirus disease evolution, transmission, detection, control and prevention","volume":"13","author":"Sharma","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.msard.2024.105733_bib0022","unstructured":"U.S. Food and Drug Administration. Fact sheet for heathcare providers: emergency use authorization of PEMGARDA (PEMIVIBART). Mar 2024."},{"issue":"4","key":"10.1016\/j.msard.2024.105733_bib0017","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1136\/jnnp-2022-330100","article-title":"SARS-CoV-2 omicron breakthrough infections in patients with multiple sclerosis","volume":"94","author":"van Kempen","year":"2023","journal-title":"J. Neurol. Neurosurg. Psychiatry"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034824003109?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034824003109?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T03:21:34Z","timestamp":1723605694000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034824003109"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":22,"alternative-id":["S2211034824003109"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2024.105733","relation":{},"ISSN":["2211-0348"],"issn-type":[{"type":"print","value":"2211-0348"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Analysis of Evusheld safety and efficacy in multiple sclerosis patients","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2024.105733","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105733"}}